Check-Cap (NASDAQ:CHEK) had its price target lowered by HC Wainwright from $7.00 to $5.50 in a report issued on Tuesday morning. The brokerage currently has a buy rating on the medical research company’s stock.

Several other equities research analysts have also commented on the company. Maxim Group restated a buy rating and set a $5.00 target price on shares of Check-Cap in a research report on Wednesday, September 27th. Zacks Investment Research upgraded Check-Cap from a hold rating to a buy rating and set a $2.00 target price on the stock in a research report on Tuesday, October 3rd. Finally, ValuEngine lowered Check-Cap from a sell rating to a strong sell rating in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Check-Cap currently has a consensus rating of Buy and an average price target of $4.63.

Shares of Check-Cap (CHEK) opened at $1.02 on Tuesday. Check-Cap has a 52-week low of $1.01 and a 52-week high of $2.70.

A hedge fund recently raised its stake in Check-Cap stock. Sabby Management LLC lifted its holdings in shares of Check-Cap Ltd. (NASDAQ:CHEK) by 467.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,418,893 shares of the medical research company’s stock after purchasing an additional 1,169,061 shares during the period. Check-Cap accounts for about 0.1% of Sabby Management LLC’s portfolio, making the stock its 24th biggest position. Sabby Management LLC owned 8.36% of Check-Cap worth $2,724,000 at the end of the most recent quarter. Institutional investors own 19.13% of the company’s stock.

WARNING: “Check-Cap (CHEK) Price Target Cut to $5.50 by Analysts at HC Wainwright” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.